Measuring ROI from AI Investments in Life Sciences

Why AI ROI Is Particularly Hard to Measure in Pharma

AI ROI in pharma faces three structural challenges that traditional capital investments don’t. First, the benefits are often distributed across functions — the AI improves cycle time in one team, decision quality in another, audit-readiness in a third — and no single function captures the full value. Second, regulated environments impose validation costs that are nontrivial and often invisible to non-Quality stakeholders. Third, AI capability changes faster than capital investment cycles, which makes traditional five-year payback analysis poorly suited to the technology.

These structural issues are correctable, but only if the measurement framework acknowledges them upfront. Cases that paper over the complexity tend to be wrong, and they get caught.

The Three Common Measurement Failures

Failure 1: Counting hours saved as cash recovered

The most common ROI overcount in pharma comes from monetizing time savings as if they convert directly to cash. They don’t, in most cases. A reviewer who saves four hours per week on document review does not produce 200 hours of incremental value at the end of the year — they typically absorb the time into other activities, take on additional reviews, or simply work less intensely. The hours are real. The cash is not.

The honest accounting is to claim time savings only when they free a measurable, redeployable resource — for example, removing the need for a contractor, allowing capacity expansion without adding headcount, or enabling a function to take on a backlog without growth.

Failure 2: Hidden validation cost

Tier 3 AI use cases in regulated environments require CSV-equivalent validation, lifecycle change controls, and ongoing revalidation triggers. These costs are routinely missing from business cases — partly because the team writing the case isn’t the team that will execute the validation, and partly because vendors quote implementation costs without validation overhead.

For most Tier 3 use cases, validation runs 30-60% of total implementation cost in year one and 15-25% of total operating cost in subsequent years. Excluding it from the ROI math materially overstates the return.

Failure 3: Static benefits, dynamic costs

AI vendor pricing has been remarkably dynamic — both up and down — over the past 18 months. Models change. Token pricing changes. Hosting costs change. Many ROI analyses assume static operational costs over a five-year horizon, which is increasingly unrealistic.

The right approach is to model operational costs with a sensitivity band. Best-case, expected-case, worst-case for vendor pricing trajectory. Then compute ROI under all three scenarios. If the use case only delivers ROI in the best case, you don’t have a robust investment.

A Real Total Cost of Ownership Framework

Below is the cost component checklist Sakara Digital uses with clients building AI ROI cases. Each component has a recommended estimation method.

Benefit Categories That Matter

Four categories of benefit hold up under scrutiny. Each has its own measurement standard.

Cycle time reduction

Measure the time from start to finish of a defined process. Compare baseline to AI-enabled state. Convert to economic value only if cycle time reduction enables capacity expansion, faster product launch, or earlier revenue capture — not if it just frees time that gets reabsorbed into the same role.

Decision quality improvement

Measure accuracy, error rate, or compliance variance against a defensible benchmark. Convert to economic value through cost-of-error analysis (rework, regulatory exposure, compliance findings) or revenue-of-quality analysis (faster approvals, fewer holds).

Capacity reallocation

The most defensible economic benefit. When AI removes the need for a specific FTE, contractor, or vendor capacity, the savings are real and recoverable. Always quantify capacity reallocation as the redeployed work or avoided cost, not as a productivity ratio.

Risk mitigation

Probability-weighted economic value of avoided regulatory findings, audit exposures, compliance failures, or quality events. This is the hardest category to quantify but often the most strategically important. Use industry benchmarks as anchors and document assumptions explicitly.

Choosing the Right Time Horizon

AI investment ROI is highly sensitive to time horizon assumptions. A use case that returns 1.4x at three years may return 2.8x at five years — but the technology landscape may have shifted enough by year five that the assumption set is invalid.

For Tier 1 use cases (low-risk, high-iteration), three-year horizon. For Tier 2, three to five years. For Tier 3 (validated GxP-adjacent or autonomous), five years with sensitivity bands. In all cases, the analysis should explicitly model the option value of being able to switch vendors or platforms in years three to five — that flexibility has economic value and should not be assumed away.

Establishing a Defensible Baseline

Many AI ROI cases compare against a baseline that flatters the new system. Common errors include comparing to an unstaffed or undertrained current state, ignoring recent process improvements that would have happened anyway, and treating the most painful 5% of cases as the typical case.

A defensible baseline meets three criteria. It represents the steady-state operation of the current process with normal staffing and training. It accounts for any non-AI improvements that are reasonably likely to occur in the comparison period. And it uses a representative sample of cases, not the worst-case examples.

Tracking ROI After Deployment

The discipline that separates credible AI programs from cargo-cult AI programs is post-deployment ROI tracking. Most pharma organizations stop measuring after the launch. The result is that the same use cases keep getting refunded based on initial promise rather than realized value.

A simple post-deployment tracking framework: at three months, six months, twelve months, and annually thereafter, refresh the ROI calculation with actual data. Compare actual to projected. Document the variance and its drivers. Use the variance to inform the next AI investment in the portfolio.

Use cases that consistently underperform projections should be sunset, restructured, or rebaselined — not quietly continued. The organizational discipline of doing this rigorously is itself a competitive advantage.

References